Comparative Pharmacology
Head-to-head clinical analysis: PRIMAXIN versus VABOMERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRIMAXIN versus VABOMERE.
PRIMAXIN vs VABOMERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. Cilastatin prevents renal metabolism of imipenem by inhibiting dehydropeptidase I.
Vabomere is a combination of meropenem, a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and vaborbactam, a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase (KPC).
1 g (imipenem 500 mg + cilastatin 500 mg) IV every 6 hours for adults with normal renal function. Maximum 4 g/day.
Vabomere (meropenem and vaborbactam) 4 g (meropenem 2 g and vaborbactam 2 g) intravenously every 8 hours infused over 3 hours.
None Documented
None Documented
Terminal elimination half-life: 1 hour. In patients with impaired renal function, half-life extends up to 4-6 hours in moderate impairment and >10 hours in severe impairment.
The terminal elimination half-life is approximately 1 hour for meropenem and 2 hours for vaborbactam in patients with normal renal function. This short half-life supports three-times-daily dosing in patients with creatinine clearance ≥50 mL/min.
Renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion) and 20-30% biliary/fecal.
Vabomere (meropenem and vaborbactam) is primarily excreted renally. Approximately 40-50% of meropenem and 75-95% of vaborbactam are excreted unchanged in urine. Biliary/fecal excretion is minimal (<2% for both).
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic